<DOC>
	<DOCNO>NCT00316433</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness combination oxaliplatin irinotecan ( CPT-11 ) patient previously untreated , advance small cell lung cancer .</brief_summary>
	<brief_title>Oxaliplatin/CPT-11 Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Previously untreated extensive small cell lung cancer No prior chemotherapy No prior radiotherapy except treatment brain metastasis Prior treatment extensive stage small cell lung cancer Known hypersensitivity component oxaliplatin CPT11 Greater grade 2 peripheral neuropathy Known HIV Hepatitis B C ( active , previously treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>